SG Americas Securities LLC Increases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

SG Americas Securities LLC increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 174.9% in the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 19,182 shares of the company's stock after buying an additional 12,204 shares during the quarter. SG Americas Securities LLC's holdings in Mirum Pharmaceuticals were worth $864,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Jones Financial Companies Lllp boosted its holdings in shares of Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after acquiring an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $35,000. GF Fund Management CO. LTD. purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth approximately $42,000. AlphaQuest LLC boosted its holdings in Mirum Pharmaceuticals by 969.6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock worth $76,000 after purchasing an additional 1,658 shares during the last quarter. Finally, Summit Investment Advisors Inc. grew its position in Mirum Pharmaceuticals by 8.1% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after purchasing an additional 312 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MIRM. Raymond James Financial reiterated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright reiterated a "buy" rating and set a $73.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, May 19th. Robert W. Baird increased their target price on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an "outperform" rating in a report on Thursday, February 27th. Finally, JMP Securities raised their target price on Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a "market outperform" rating in a research report on Friday, May 9th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $65.50.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock traded down $0.46 during mid-day trading on Friday, reaching $50.34. 737,624 shares of the company's stock traded hands, compared to its average volume of 480,875. The company has a debt-to-equity ratio of 1.32, a quick ratio of 3.04 and a current ratio of 3.22. The firm has a market capitalization of $2.49 billion, a PE ratio of -31.27 and a beta of 0.95. Mirum Pharmaceuticals, Inc. has a 12 month low of $32.00 and a 12 month high of $54.23. The firm has a 50 day moving average price of $44.31 and a two-hundred day moving average price of $45.03.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.05. The company had revenue of $111.59 million for the quarter, compared to the consensus estimate of $98.47 million. Mirum Pharmaceuticals had a negative return on equity of 33.63% and a negative net margin of 20.39%. Mirum Pharmaceuticals's quarterly revenue was up 61.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.54) earnings per share. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.